- < General Internal Medicine
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • March 27, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03666-y. Epub ahead of print. Erratum for: Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. PMID: 40140623.
Related Posts
Kellner DA, Dente E, Tran V, Welsh T, Tran V, Saha A, Baker JF, Elashoff DA, Ranganath VK. Effect of Glucagon-Like Peptide 1 Receptor Agonists[...]
Buen KI. "Deeds, Not Words: A Commitment to Our Mission". J Hosp Palliat Nurs. 2025 Oct 1;27(5):219-220. doi: 10.1097/NJH.0000000000001150. Epub 2025 Aug 21. PMID: 40928264.
Li J, Noveir SD, Bouri N, Cheng K, Saini I. Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections. J Gen[...]
